Product Development Advisory Committee

The Product Development Advisory Committee (PDAC) provides expertise to the Oversight Committee on the growing gap between translational discovery and later stage clinical development of new oncology drugs in Texas. Primarily, it is making recommendations on the breadth of life science expertise needed in Texas to advance the state’s ability to improve cancer patient outcomes from promising scientific discoveries. 

Members:

Andrew Strong, JD, Chair
Partner, Hogan Lovells, LLP
Founding CEO & President, Kalon Biotherapeutics

Michele Park, Ph.D., Vice-Chair
Partner
NEA

Claire Aldridge, Ph.D.
Chief of Staff and SVP, Business Operations
Taysha Gene Therapies

David Arthur
CEO
Salarius Pharmaceuticals

Bruce Butler, Ph.D.
Vice President, Research and Technology
Director, Office of Technology Management
UT Health Sciences Center at Houston

Gabby Everett, Ph.D.
Site Director, BioLabs Pegasus Park

Victoria Ford
President and CEO, Texas Healthcare & Bioscience Institute

Julie Goonewardene
Associate Vice Chancellor for Innovation and Strategic Investment
The University of Texas System

Heather Hanson
President
BioMedSA

Dan Hargrove, JD
Co-founder and President
Trauma Insight, LLC and LumaBridge, LLC

Paul Lammers, M.D.
CEO, President and Director, Triumvira Immunologics
Former CEO and President, Mirna Therapeutics

David Lowe, Ph.D.
Co-Founder, Aeglea Biotherapeutics
Managing Director, AllosteRx Capital

Tom Luby, Ph.D.
Director
Texas Medical Center (TMC) Innovation

Jonathan MacQuitty, Ph.D.
Venture Partner
Lightspeed Venture Partners

Dennis McWilliams
Venture Partner
Sante Ventures

Jon Mogford, Ph.D.
Chief Operating Officer and Senior Vice President
Texas A&M University Health Science Center

Tracy Saxton, Ph.D.
CEO, Lengo Therapeutics
Adviser, Frazier Healthcare Partners

Emma Schwartz
President
Medical Center of the Americas Foundation

Greg Stein, M.D.
CEO
Curtana Pharmaceuticals

Ann Tanabe
CEO
BioHouston, Inc.